Table 1.
Participant baseline demographics (safety population).
| mRNA-1283 |
mRNA-1273 |
||||
|---|---|---|---|---|---|
| 10 µg (n = 21) |
30 µg (n = 22) |
100 µg (n = 21) |
Placebo + 100 µg (n = 18) |
100 µg (n = 22) |
|
| Age, y | |||||
| Mean ± SD | 38.1 ± 9.5 | 34.8 ± 10.4 | 34.8 ± 10.8 | 33.7 ± 10.4 | 42.0 ± 10.3 |
| Median (range) | 41.0 (23–51) | 30.5 (21–54) | 36.0 (19–51) | 30.5 (19–49) | 43.0 (22–55) |
| Sex, n (%) | |||||
| Male | 9 (42.9) | 13 (59.1) | 12 (57.1) | 12 (66.7) | 14 (63.6) |
| Female | 12 (57.1) | 9 (40.9) | 9 (42.9) | 6 (33.3) | 8 (36.4) |
| Race, n (%) | |||||
| White | 15 (71.4) | 16 (72.7) | 16 (76.2) | 10 (55.6) | 16 (72.7) |
| Black/African American | 1 (4.8) | 2 (9.1) | 1 (4.8) | 0 | 1 (4.5) |
| Asian | 0 | 1 (4.5) | 2 (9.5) | 1 (5.6) | 1 (4.5) |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 (5.6) | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 (5.6) | 0 |
| Multiracial | 1 (4.8) | 0 | 0 | 2 (11.1) | 0 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Not reported | 4 (19.0) | 3 (13.6) | 2 (9.5) | 3 (16.7) | 4 (18.2) |
| Ethnicity, n (%) | |||||
| Not Hispanic or Latino | 14 (66.7) | 15 (68.2) | 16 (76.2) | 13 (72.2) | 14 (63.6) |
| Hispanic or Latino | 7 (33.3) | 7 (31.8) | 5 (23.8) | 4 (22.2) | 7 (31.8) |
| Not reported | 0 | 0 | 0 | 1 (5.6) | 1 (4.5) |
| Weight, kg | |||||
| Mean ± SD | 81.3 ± 14.4 | 76.9 ± 17.1 | 73.4 ± 15.5 | 82.5 ± 19.9 | 81.5 ± 11.9 |
| Height, cm | |||||
| Mean ± SD | 173.5 ± 11.2 | 171.8 ± 10.0 | 172.1 ± 12.1 | 175.0 ± 9.2 | 172.3 ± 8.4 |
| BMI, kg/m2 | |||||
| Mean ± SD | 27.0 ± 3.8 | 25.9 ± 4.1 | 24.6 ± 3.3 | 26.7 ± 4.5 | 27.5 ± 3.6 |
All randomly assigned participants who received dose 1 of the study vaccination were included in the safety population.
Abbreviations: BMI, body mass index; mRNA, messenger RNA; SD, standard deviation.